It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a functioning liver for transplantation within a human being.
Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.
Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.
Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.
What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
SWISSto12 Receives €30M to Make ESA Satellite with 3D Printing
SWISSto12 has a wonderful niche in making waveguides and other optimized satellite components with 3D printing, securing it deals to make satellite components for Lockheed and antennas with the European...
China’s SpaceX 3D Prints over 30 Parts for Rocket Engine
In an effort to become China’s SpaceX, Galactic Energy has raised over $188 million in its Series B round and has now commissioned service bureau Falcontech to 3D print over...
2023 Dream 3D Printing Mergers and Acquisitions: Will Apple Buy…?
2022 saw far fewer mergers and acquisitions, as well as initial public offerings, than the cash-flush year before. However, this year’s drought may mean next year’s glut, as inflation slows...
3D Printing News Unpeeled: LocLab and Hexagon, SpaceTech and Glowscape
eSoutheast University (SEU) Nanjing and ETH Zurich have made Glowscape this is a large format Kuka robot 3D print using Natureworks Ingeoe PLA pellets. The interactive lit piece uses its translucency...